In: Nursing
CASE STUDY:
Poppy is a 9 year old female, weight 40Kg.
She presented to ED with worsening respiratory symptoms over the past few hours. Her parents state she is unable to
talk in full sentences or undertake a peak flow. In ED Poppy has been given 3 x 20 minutely nebulised Salbutamol with
6LPM of O2, IVF commenced, Stat dose of Prednisone administered, Chest X-ray shows hyperinflation of both lung
fields. She was admitted to ICU due to her deteriorating respiratory function with a diagnosis of acute exacerbation
of asthma.
EXCERPT OF RELEVANT ICU NOTES
Past History
Diagnosed with asthma age 2 (infrequent intermittent asthma).
7
Current medications: - Ventolin PRN.
IUTD (immunisations up to date)
Nursing Assessment
A. Clear, speaking in single words
B. RR 42bpm, SpO2 87% RA, 92% on 6LPM O2 + nebuliser, auscultation decreased AE bibasally, inspiratory and
expiratory wheeze
C. HR 160bpm, ST, peripherally warm
D. GCS 14/15 (E4, V4, M6)
E. Accessory muscle use, shoulder shrugging on inspiration, tracheal tug
F. IVF NaCl 53 ml/hr
G.
a. Mg- low 0.60mmol/L (0.70-1.10mmol/L) all other pathology is normal.
b. BGL 9.0mmol/L
c. Beta-agonist- Salbutamol
d. Anticholinergic - Atrovent
e. IV Hydrocortisone
f. ABG shows respiratory acidosis, (PH 7.32, PaCO2 49, PaO2 70, HCO3 27, BE -2.1, Lactate
1.4)
Plan
- Keep SpO2 92-95%%
- Beta- antagonist Salbutamol continuous via nebuliser
- Anticholinergic Ipratropium bromide (Atrovent) 500ug 4/24
- Hydrocortisone 100mg 6/24
- MgSO4 6.4mmol/20 minutes
- IVF 53ml/hr
- Repeat ABGs in 1hour
- Monitor BGL
- Peakflow /spirometry
Ipratropium Bromide via nebuliser
– What clinical response you expect from this medication?
– What continuing clinical observations will you need to undertake?
Inhaled short-acting b2-agonists (SABA) are the most potent bronchodilators used today to treat acute symptoms of asthma and albuterol, a partial b2-agonist, is the most frequently prescribed in asthma . It is used in for acute asthma symptoms, SABA have been associated with a significant degree of interpatient variability. It characterized the SABA dose to bronchodilator response relationship under controlled conditions. However,this characterized the relationship between inhaled doses of albuterol and bronchodilation in 81 children and adults with moderate to severe persistent asthma using a population pharmacodynamic approach. This including maximal dose for bronchodilation, and to quantify and identify sources of interpatient pharmacodynamic variability.
Upon completion of the patient observation training course, delegates will have the capacity and capability to: